Mimedx Group Inc (NASDAQ:MDXG) Sellers Covered 6.82% of Their Shorts

March 21, 2018 - By Clifton Ray

 Mimedx Group Inc (NASDAQ:MDXG) Sellers Covered 6.82% of Their Shorts

Investors sentiment decreased to 1.97 in 2017 Q3. Its down 0.05, from 2.02 in 2017Q2. It fall, as 21 investors sold MiMedx Group, Inc. shares while 44 reduced holdings. 48 funds opened positions while 80 raised stakes. 77.22 million shares or 15.28% more from 66.99 million shares in 2017Q2 were reported.
Ruggie Grp Inc owns 6,900 shares or 0.05% of their US portfolio. Thompson Invest invested in 0.7% or 314,462 shares. Moreover, Pub Employees Retirement Association Of Colorado has 0% invested in MiMedx Group, Inc. (NASDAQ:MDXG) for 24,331 shares. Murphy Capital Mngmt invested in 0.04% or 22,700 shares. Great West Life Assurance Can owns 172,953 shares. Blackrock has invested 0.01% in MiMedx Group, Inc. (NASDAQ:MDXG). Aqr Cap Ltd Llc has 57,731 shares for 0% of their portfolio. Bridgeway Mgmt Incorporated stated it has 14,300 shares or 0% of all its holdings. Virtu Limited Com invested in 25,344 shares. 217,560 were accumulated by Legal And General Grp Inc Pcl. Ubs Asset Mngmt Americas holds 0% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG) for 50,261 shares. Prudential Financial Inc, New Jersey-based fund reported 1.07 million shares. Convergence Invest Prtn Limited Liability reported 74,680 shares. Nordea Invest Mngmt Ab holds 12,953 shares. Tci Wealth Advsrs Inc invested in 0% or 71 shares.

The stock of Mimedx Group Inc (NASDAQ:MDXG) registered a decrease of 6.82% in short interest. MDXG’s total short interest was 38.96M shares in March as published by FINRA. Its down 6.82% from 41.81M shares, reported previously. With 2.15M shares average volume, it will take short sellers 18 days to cover their MDXG’s short positions. The short interest to Mimedx Group Inc’s float is 39.87%.

The stock increased 0.69% or $0.05 during the last trading session, reaching $7.27. About 1.38 million shares traded. MiMedx Group, Inc. (NASDAQ:MDXG) has risen 107.87% since March 21, 2017 and is uptrending. It has outperformed by 91.17% the S&P500.

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. The company has market cap of $807.22 million. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. It has a 23.38 P/E ratio. The companyÂ’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.

MiMedx Group, Inc. (NASDAQ:MDXG) Ratings Coverage

Among 9 analysts covering MiMedx Group (NASDAQ:MDXG), 5 have Buy rating, 2 Sell and 2 Hold. Therefore 56% are positive. MiMedx Group had 30 analyst reports since July 29, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, December 13 report. The rating was maintained by First Analysis on Wednesday, January 20 with “Overweight”. The rating was downgraded by Needham on Tuesday, February 20 to “Hold”. The stock of MiMedx Group, Inc. (NASDAQ:MDXG) earned “Buy” rating by Needham on Wednesday, October 14. The rating was maintained by Needham with “Buy” on Monday, October 30. The firm earned “Strong Buy” rating on Monday, November 16 by Needham. The stock of MiMedx Group, Inc. (NASDAQ:MDXG) has “Buy” rating given on Friday, August 18 by Piper Jaffray. The firm earned “Buy” rating on Tuesday, April 19 by Lake Street. On Monday, June 26 the stock rating was maintained by Needham with “Buy”. The stock has “Buy” rating by Needham on Thursday, January 18.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.